STANDARD OPERATING PROCEDURE SOP 320. Developing a Research Protocol
|
|
- Clinton Scott
- 6 years ago
- Views:
Transcription
1 STANDARD OPERATING PROCEDURE SOP 320 Developing a Research Protocol Version 2.1 Version date Effective date Number of pages 14 Review date April 2019 Author NNUH UEA Joint Research Office Approved by Julie Dawson Role Acting Research Services Manager Signature Date Authorised for NNUH and UEA by Role Professor Alastair Forbes Chief of Research and Innovation Signature Date COPIES PRINTED FROM THE WEBSITE ARE VALID ONLY ON THE DAY OF PRITNTING SOP 320 v2.1 Effective Date: Page 1 of 14
2 It is the responsibility of all users of this SOP to ensure that the correct version is being used. All staff should regularly check the NNUH R&D website for information relating to the implementation of new or revised versions of SOPs. Staff must ensure that they are adequately trained in the new procedure and must make sure that all copies of superseded versions are promptly withdrawn from use. The definitive versions of all Joint NNUH/UEA health care research SOPs appear online. If you are reading this in printed form please check that the version number and effective date is the most recent one as shown on the NNUH R&D website. TABLE OF CONTENTS 1 ABBREVIATIONS 3 2 INTRODUCTION 3 3 SCOPE 3 4 PROCEDURE FOR PROJECT PROPOSAL FOR FUNDING APPLICATION 5 PROCEDURE FOR PROTOCOL DEVELOPMENT 4 6 PROCEDURE FOR PROTOCOL AMENDMENT 5 7 REFERENCES 5 8 RELATED DOCUMENTS 5 9 LIST OF APPENDICES 6 Appendix 1: Guidance for Protocol Structure for Non CTIMPs 7 3 Appendix 2: Requirements for a Protocol Structure for CTIMPs and Medical Device Trials and Further Guidance 10 Appendix 3: Change Control, Revision and Review Sheet 14 SOP 320 v2.1 Effective Date: Page 2 of 14
3 1 ABBREVIATIONS CRTU Clinical Research and Trials Unit CTU Clinical Trial Unit CRF Case Report File GCP Good Clinical Practice ICH International Conference for Harmonisation MHRA Medicines and Healthcare Products Regulatory Agency NNUH Norfolk and Norwich University Hospital R&D Research and Development SOP Standard Operating Procedure TMF Trial Master File UEA University of East Anglia ISRCTN International Standard Randomised Controlled Trial Number 2 INTRODUCTION This SOP describes the processes for writing health care research proposals and protocols by researchers at UEA and NNUH. These processes aim to ensure that, as well as answering specific research questions created and developed by the research team, the research is carefully designed to safeguard the health and safety of the participants in compliance with the conditions and principles of GCP and the applicable EU guidelines and regulations. 3 SCOPE This SOP applies to all healthcare research sponsored by NNUH or UEA which falls within the scope of the Research Governance Framework (2nd edition 2005) or its successors. Where additional legislation applies - for example, the Medicines for Human Use (Clinical Trials) Regulations 2004 (and amendments thereof) or the Medical Devices Regulations required procedures will be indicated. External sponsors may require use of their own SOPs and this will be specified in site agreements. It is the responsibility of the local PI to ensure that study specific SOPs can be operated without conflict to this SOP and in accordance with all organisational polices related to research. 4 PROCEDURE FOR PROJECT PROPOSAL FOR FUNDING APPLICATION A proposal must be written by the Research Team prior to applying for any funding. The research proposal forms an essential part of a research study. The proposal for a qualitative research study will need to allow for variation as qualitative research designs are often altered and develop as the research commences. Whether for a qualitative study, quantitative study or a mixed methods study, the research proposal is a plan for engaging in systematic inquiry and should demonstrate that: the research is worth doing the researcher is competent to conduct the study - by providing evidence of the skills and experience of the researcher and his or her research team the results of the study will have validity SOP 320 v2.1 Effective Date: Page 3 of 14
4 the potential hazards identified in the risk assessment can be mitigated through study design, safety monitoring procedures and project management plans the study is carefully planned and can be executed successfully. Before beginning your research proposal you should consider the following points: What is your research question? Why does it matter? How will you address this question? (i.e. what methods will you use?) How important is this activity to the NHS and to service users? Is your research question clear? Are your research methods appropriate? What are the identifiable hazards and risks for the participants, investigators and organisations involved? The proposal for research funding should be developed in accordance with the guidance on trial planning and design within the Clinical Trials toolkit along with any additional funder requirements. Where the study is being submitted for external funding, UEA has established peer review committees that will consider the proposal prior to submission. The process of peer review is available from the UEA Research and Enterprise Intranet or by contacting the Research Grants Co-ordinator at NNUH, Research and Development ( research-and-innovation/key-contacts/). This process is mandatory for certain external funding areas and so will need to be factored in by the Research Team to ensure appropriate peer review before external funder deadlines. Where the study is to be adopted by the Norwich Clinical Trials Unit, the Norwich CTU will need to be involved in the development of the proposal. After any peer review, the proposal must also receive approval by NNUH and/or UEA before submission to the external funder. The proposal may be updated following comments from the funding body. NNUH and UEA will need to approve the updated proposal prior to re-submission to the funding body. 5 PROCEDURE FOR PROTOCOL DEVELOPMENT A research protocol is an essential document which provides the research team with a plan for undertaking the study. The protocol is also a legal document that, once approved by regulatory and ethical bodies, all parties and organisations involved in the study agree to comply with. Investigators should sign and date the signature page of the current protocol and organisations should refer to the protocol in their agreements about the study. The protocol must be written by the Research Team prior to applying for any approval and prior to starting the study. The research protocol for ethical and research governance review should be developed in accordance with the HRA guidelines and that of the lead NHS Trust. Where the study is adopted by the Norwich Clinical Trials Unit, the Norwich CTU will need to be involved in the development of the protocol. SOP 320 v2.1 Effective Date: Page 4 of 14
5 The protocol should be version controlled (see SOP 800 Documentation Management). The final version of the protocol must be reviewed, amended as necessary, and approved by the Research Team, normally including the CI, the study statistician and the study pharmacist (the latter two roles being essential for CTIMPs). For studies involving a health economic analysis, the analysis output should also be reviewed by the Health Economist. The final version of the protocol sent for regulatory and ethical approvals should be signed and dated by the CI and stored in the Trial Master File (see SOP 305 Creating and Maintaining a Trial Master File). The process for approval of the protocol for ethical and research governance review is part of the start-up activities for a Clinical Trial (SOP 325), confirmation of Sponsorship of Research (SOP 400), and obtaining MHRA approval for CTIMPs and Medical Devices trials (SOP405). An early version of the protocol may be updated following comments and feedback from regulatory bodies prior to the start of the project. All versions should be signed and dated and stored in the Trial Master File. Guidance on the content of the protocol is provided in Appendix 1 (non CTIMPs), Appendix 2 (CTIMPs). 6 PROCEDURE FOR PROTOCOL AMENDMENT For CTIMPS, the process for seeking approval for amendments to the research protocol is detailed in SOP 405 (Obtaining and Maintaining Medicines and Healthcare Products Regulatory Approvals Agency (MHRA) Approval for a Clinical Trial). Amendments must be reviewed, further amended as necessary, and approved by the Research Team including, as a minimum the CI, the study statistician, the study pharmacist, and the Sponsor before the amendments are submitted to the regulatory and ethical bodies. The final version submitted for regulatory and ethical approval must be signed and dated by the CI and stored in the Trial Master File. For non-ctimps, amendments must be reviewed, further amended as necessary, and approved by the Research Team and the Sponsor before submission for research governance and ethical approval. 7 REFERENCES 1. Clinical Trial Toolkit: Information required in a trial protocol RSS Framework-Annex5-S05-Planning Toolkit for SPONSORING Organisation, May 2011 available from 3. MRC/DH/MHRA Joint Project. Risk-adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Products. Version: 10th October RELATED DOCUMENTS SOP 305 Creating and Maintaining a Trial Master File SOP 310 Development of a Participant Information Sheet and Informed Consent Form SOP 325 Start up Activities for Clinical Trials SOP 340 Clinical Trial Reporting SOP 400 Joint Arrangements for Research Authorisation of Research Sponsorship SOP 320 v2.1 Effective Date: Page 5 of 14
6 SOP 405 SOP 800 Obtaining and Maintaining Medicine and Healthcare Products Regulatory Agency (MHRA) Approval for a Clinical Trial Documentation Management Additional advice and documentation created to support Proposal and Protocol Development is available from the Norwich Clinical Trials Unit. 9 LIST OF APPENDICES Appendix 1 Appendix 2 Appendix 3 Guidance for Protocol Structure for Non CTIMPs Requirements for a Protocol Structure for CTIMPs and Medical Device Trials and Further Guidance Change Control, Revision and Review Sheet SOP 320 v2.1 Effective Date: Page 6 of 14
7 Appendix 1 Guidance for protocol structure for non CTIMPs The following is a suggested format for a protocol for a non CTIMP.. A) Protocol Identification: code number, version numbers and dates, signatures i) Protocol code number A protocol code number is required on each protocol. This code number should be unique. Contact the Sponsoring organisation for advice on the protocol code number to be used. ii) Protocol Version Numbers and Dates It is advisable to allocate version numbers and version dates for protocols during the drafting process. The final protocol that is submitted to the ethics committee should ideally be numbered version 1.0 and dated with the date of finalisation of the protocol. If any protocol amendments are made, then the protocol version number and date must be updated accordingly. Similarly; Participant Information Sheets and Consent Forms must be marked with the appropriate version numbers and dates. iii) Protocol Signature The protocol and any subsequent amendments must be signed by the Sponsor. Provide the name and title of person(s) authorised to sign the protocol and a space for their signature and date. i) Title The title clearly identifies the study and may contain a brief description of the study design and objectives. ii) Investigators Everyone who has made a material contribution to the design of at least one component of the study should be named and their contact details given, iii) Abstract/Summary Summarise the aims or objectives of the study and give a brief outline of the design and methods. iv) Background/Introduction The introduction should outline the background to the research, including a critical review of the current knowledge or literature, including published and unpublished work in the area. Any gaps in the evidence should be identified as should the potential value of furthering knowledge in this field, such as theoretical or practice based applications of the potential research outcomes. An explanation of the reasons for undertaking the work should also be included in this section, ideally incorporating a reflective stance whereby the researcher/s reflect upon their own reasons for undertaking the research and interest in the field. v) Aims & Objectives SOP 320 v2.1 Effective Date: Page 7 of 14
8 Outline broad objectives that should follow on from the identified gaps in the literature and rationale for the study. Stated objectives should also allow for unexpected emergent findings to be incorporated as part of the research findings. vi) Study Design & Methods Study Design. Summary of chosen study design to answer particular research question. Setting. Where will the research take place? Participants. Information regarding your participants should be given. For example; o Describe the expected study population, including a rationale of why they are relevant to your research question(s). o Describe the methods by which participants will be identified and recruited and what criteria will be used for deciding whether or not individuals are eligible to participate. You will need to state your expected sample size, and provide some justification. For example, a case study approach may be applicable if in-depth knowledge about a particular topic is sought, but a limited generalised statement should be included. o Describe the nature of expected adverse events along with the reporting procedures that will be used. o Describe the assessment and follow up requirements (as applicable) and define the end of the study. o Describe the consent process and relevant timelines. o Issues such as the potential transferability of results to alternative populations should be considered. Sampling methods. You will need to explain and justify what sampling methods you plan to use. Justifications may be framed in terms of gaining access to particular populations, or in terms of fit with the research design. Methods of data collection. What data will be collected, why and how it will be collected. For example: if you are undertaking semi-structured interviews about a particular topic, the interview guide should be discussed, with information about how participants may be given freedom to discuss unforeseen issues of importance to them. If you are using any equipment, e.g. tape or video recorders, it should be clearly described. vii) viii) Data Collection, Management & Analysis Explain how the data will be collected and managed and who will have access to it. The method and approach to data analysis should also be discussed and may include the following points: Method of data recording Plan of statistical analysis, including assumptions of analysis Data analysis package Planned presentation of the data, i.e. written reports, vignettes, etc Where data on participants is being held electronically, the data management requirements within the 800 SOP series need to be adhered to. Study Administration & Ethical Issues Describe the arrangements for the day-to-day management of the study. SOP 320 v2.1 Effective Date: Page 8 of 14
9 Outline the methods by which the participants interests will be safeguarded. For example; the process of risk limitation; how you will maintain confidentiality or anonymise participants data and how you will deal with any apparent psychological harm State whether there has been user involvement in design of the study, and whether user involvement will be incorporated as an ongoing aspect of the research. If applicable, state whether you have adhered to any set of ethical guidelines If applicable, the proposal should clearly state who is funding the research study and what interest they have in its outcome. Confirm the sponsorship arrangements for the study (i.e. which organisations are taking on formal sponsorship responsibilities for the study (SOP 400) ix) Resource Requirements The resource implications to the host organisation and any other involved departments should be defined in this section. In addition you must outline the timetable/schedule of the research and all costs. x) Study Plan You may wish to include a study plan, showing a brief summary or flow chart of the order, site and timing of all study procedures. xi) xii) Supervision for student projects Where applicable, the protocol should name the individual(s) who will supervise the research project and the intended arrangements for the supervision. Dissemination & Outcome (SOP 340 Clinical Trial reporting) How will the study s findings be made available? State whether you intend to publish or present the findings including any report of findings to the participants. Any implications for future practice and theoretical knowledge advancement should also be suggested. xiii) Appendices (SOP 310) Include consent forms and participant information sheets as appendices. SOP 320 v2.1 Effective Date: Page 9 of 14
10 Appendix 2 Requirements for a protocol structure for CTIMPs and/or Medical Device Trials and Further Guidance A. Contents of the protocol The trial will be conducted in compliance with the approved protocol, the Declaration of Helsinki (2008) the principles of Good Clinical Practice (GCP) as laid down by the Commission Directive 2005/28/EC with the implementation in national legislation in the UK by Statutory Instrument 2004/1031 and subsequent amendments, the UK Data Protection Act, and the National Health Service (NHS) Research Governance Framework for Health and Social Care (RGF). International sites will comply with the principles of Good Clinical Practice (GCP) as laid down by the ICH topic E6 (Note for Guidance on GCP), Commission Directive 2005/28/EC, the European Directive 2001/20/EC (where applicable) and applicable National regulations. The contents of a trial protocol for a CTIMP and/or Medical Device Trial should include the following information: General information Background information Trial objective and purpose Trial design Selection of sites/clinicians Selection and withdrawal of participants Randomisation and Unblinding Treatment of participants Assessments and Follow-Up (efficacy, safety and quality of life) Safety Reporting and Follow-Up Statistics Direct access to source data/documents Quality control and quality assurance (risk assessment, monitoring) Regulatory issues (CTA, ethics, consent, confidentiality, indemnity, sponsor, funding, audit & inspection) Data handling and record keeping SOP 320 v2.1 Effective Date: Page 10 of 14
11 Trial Management Publication policy References Appendices B. Protocol identification: code number, version number and dates, signatures i) Protocol code number A protocol code number is required on each protocol. This code number must be unique and is used as the unique identifier for the protocol when the EudraCT number is issued. Therefore; a protocol code number should be allocated that is unlikely to have been used for other trials, e.g. trial acronym and year (MAG98) or the ISRCTN number. Contact the Sponsoring organization for advice on the protocol identification code to be used. ii) Protocol version numbers and dates It is advisable to allocate version numbers and version dates for protocols during the drafting process. The final protocol that is submitted to the ethics committee and for regulatory approval should ideally be numbered version 1.0 and dated with the date of finalisation of the protocol. If any protocol amendments are made, then the protocol version number and date must be updated accordingly. Similarly, Participant Information Sheets and Consent Forms must be marked with the appropriate version numbers and dates. iii) Protocol signature The protocol and any subsequent amendments must be signed for the Sponsor. Provide the name and title of person(s) authorised to sign the protocol and a space for their signature and date. C. Other General Information Provide names & addresses of key study personnel Provide names & addresses of clinical laboratories, drug supply organizations and any other institutions involved in the trial. D. Other guidance for good protocol development. i) Risk Assessment For CTIMPs, the current regulatory framework allows for a range of risk adapted approaches according to how much is known about the medicine(s) being investigated. The following classification scheme currently in use is that proposed by the MRC/DH/MHRA. SOP 320 v2.1 Effective Date: Page 11 of 14
12 Type A: risks no higher than that of standard medical care (e.g. medicinal product licensed for use in any EU Member State and within licensed range of indications, dosage and form) Type B: risks somewhat higher than that of standard medical care (e.g. medicinal product licensed for use in any EU Member State but with modifications to range of indications, dosage, form and/or in combinations where interactions are suspected OR an active substance that is part of a medicinal product licensed in the EU) Type C: risks markedly higher than that of standard medical care (e.g. medicinal product not licensed in any EU Member State) You should consider the most appropriate type of risk from the above list that is relevant to your study. This will inform the procedures for seeking MHRA approval and the detail of trial procedures for monitoring the safety of participants (Appendix 2 of the MRC/DH/MHRA Joint Project report) as well as the decisions made by the Trust on Sponsorship of your study (SOP 400). ii) Safety Reporting ICH GCP requires that both investigators and sponsors follow specific procedures when reporting adverse events/reactions in clinical trials involving IMPs. These procedures should be described un-ambiguously in the safety section of the protocol and may require additional documents that should be referred to in this section e.g. the trial safety management plan, reference safety information. Expert help should be sought from the Sponsor for this section. The definitions of adverse events and reactions that apply in the protocol should be described. Specific exceptions to seriousness criteria that will not require expedited SAE reporting should be described, for example death due to disease progression in a cancer trial where overall survival is an outcome measure or certain elective hospitalizations. The causality categories being used in the trial should be described and those which are regarded as defining an adverse event as an adverse reaction defined. For example: There may be 5 causality categories: unrelated, unlikely, possible, probable and definitely related. If the causality assessment is unrelated or unlikely to be related then for reporting purposes the event will not be regarded as an adverse reaction to trial therapy. If the causality is assessed as possible, probable or definitely related then for reporting purposes the event is classified as an adverse reaction. The source of the Reference Safety Information used to define expectedness should be stated e.g. Summary of Product Characteristics or Investigator Brochure. This document will inform the list of expected adverse events within the protocol or the development of a separate list of Expected Adverse Events (see below). Depending on the design of the study and the IMPs in use it may not be practical to list all expected AEs and the precise severity that is expected within the protocol and an SOP 320 v2.1 Effective Date: Page 12 of 14
13 additional document an Expected Adverse Events list should be referred to in the protocol, be part of the Safety Management Plan and kept in the safety reporting section of their Investigator File. This will be the source document to determine the expectedness of all serious adverse reactions, rather than a list of expected Adverse Events within the protocol. Expert pharmacovigilance help from the Sponsor should be sought. iii) Definition of end of trial The Sponsor must notify the MHRA of the end of a clinical trial within 90 days of its completion. The definition of the end of the trial must be provided in the protocol. Any change to this definition for whatever reason should be notified as a substantial amendment. In most cases, the end of the trial will be the date of the last visit of the last participant undertaking the trial. Any exceptions to this should be justified in the protocol. NB Trialists can separate the treatment and immediate follow-up period from the longterm follow-up period providing that the follow-up phase does not include any trial specific tests, and the end of the trial is defined as the last treatment visit for the last participant. Any long-term follow-up phase should then be defined as a noninterventional phase in the protocol. If designing the trial in this way, appropriate informed consent should be obtained at the start of the trial to ensure the participant is aware of both phases of the trial. iv) Protocol amendments If the protocol is substantially amended after initiation, then there are specific procedures to follow. Protocol amendments must be reported to MHRA and fees will apply. Therefore it is wise to minimise the likelihood of protocol amendments in the first version of the protocol, where possible. It is important to consider the strictness of the eligibility criteria and consider whether any flexibility should be incorporated into the protocol. Flexibility may minimise the need for protocol amendments that are considered substantial by the regulatory and ethical bodies. SOP 320 v2.1 Effective Date: Page 13 of 14
14 Appendix 3: Change Control, Revision and Review Sheet Revision Form: SOP 320 Version No Change Date Reason for Change Reviewer Signature and Date /11/2011 Updated to reflect UEA/NNUH joint working arrangements /6/2013 Updated to include section on procedure and paragraphs and associated references to risk assessment /1/2014 Major update to content and to separate procedure for proposal for external research funding (now para 4) from procedure for research protocol (now para 5). Also to develop and then separate protocol for non-ctimps to that for CTIMPs (now as Appendices 1 and 2) based on reviewer comments Updated to reflect changes to HRA approval process. All web links have been reinstated. Emily Woodhouse Research Grant Coordinator Emily Woodhouse 21/02/2017 SOP 320 v2.1 Effective Date: Page 14 of 14
STANDARD OPERATING PROCEDURE SOP 310
STANDARD OPERATING PROCEDURE SOP 310 DEVELOPMENT OF PARTICIPANT INFORMATION SHEET AND INFORMED CONSENT FORM Version 1.3 Version date 28.03.2017 Effective date 28.03.2017 Number of pages 8 Review date April
More informationIMP Management and Accountability
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationRecording, Managing and Reporting Adverse Events in the UK
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationDevelopment Safety Update Report Guidance
Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational
More informationTrial oversight SOP for HEY-sponsored CTIMPs
R&D Department Trial oversight SOP for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored in a retrieval system
More informationInspections: an academic perspective
Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk
More informationSponsorship of Clinical Research Studies
Sponsorship of Clinical Research Studies Category: Summary: Equality Impact Assessment undertaken: Policy The UK Policy Framework for Health and Social Care 2017 (UKPF) and The Medicines for Human Use
More informationStandard Operating Procedure for Archiving
Standard Operating Procedure for Archiving SOP name: NWORTH07/19 archiving Version 2 Authorship Team: Angela Gliddon & Rhiannon Whitaker Meeting date reviewed 16 th April 2008 Designated NWORTH member
More informationTrial Protocol. Version 1.2. Effective date: 18 May Dr Sarah Duggan, CTU Manager. V May 2010 Update web links.
Trial Version 1.2 Effective date: 18 May 2010 Reviewed by: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Reason for change V1.2 18 May 2010 Update
More informationEuropean Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells)
European Academy of Hospital Pharmacy Biotechnology Educational Summit Clinical trials David Gerrett (Acknowledgment Mark Howells) Objectives Have an appreciation and overview of clinical trials Understand
More informationManagement and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility
Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility Document Detail Document type Standard Operating Procedure CRF-STU-SOP-1: Management and Accountability
More informationMarie-Claire Good, RG and GCP Manager James Rickard, Deputy Chief Pharmacist Technical Services Cheryl Lawrence, Senior Research Pharmacist
Standard Operating Procedures (SOP) for: IMP Management BH/QMUL Sponsored CTIMPs SOP Number: 42a Version Number: 3.0 Effective Date: 14 th August 2017 Review Date: 14 th August 2019 Author: Reviewer: Reviewer:
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Archiving and the Destruction of Records SOP-RES-028 Version Number 2 Issue Date 08 th Dec 2015 Effective Date 22 nd January 2016 Review Date 22 nd January
More informationInvestigational Medicinal Product (IMP) Management Standard Operating Procedure
Reference Number: UHB 040 Version Number: 3 Date of Next Review: 26 Apr 2019 Previous Trust/LHB Reference Number: T 363 Standard Operating Procedure Introduction and Aim This procedure is written to support
More informationMRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council
MRC Clinical Trials Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 Medical Research Council MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 MRC GUIDELINES FOR
More informationDate: 2 nd June 2010 Version: 3 Page 1 of 16 AND LABELLING (NWORTH 3.08) Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10
Page 1 of 16 STANDARD OPERATING PROCEDURE FOR TRIAL SUPPLIES AND LABELLING (NWORTH 3.08) Approvals Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10 Quality Assurance Officer Name: D.
More informationTrial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products
1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible
More informationResearch Governance Policy and Procedure
Research Governance Policy and Procedure Version: 5 Name of originator/author: Name of executive lead: Date ratified: Review date: APPLICABLE TO: All staff. EXECUTIVE SUMMARY Dr Lisa Austin- University
More informationAn initial pilot assessment of the MHRA risk-adapted approaches to the management of clinical trials of investigational medicinal products
An initial pilot assessment of the MHRA risk-adapted approaches to the management of clinical trials of investigational medicinal products May 2011 1. Executive Summary 1.1. The NIHR Evaluation Trials
More informationR&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:
Research as a Participating site STANDARD OPERATING PROCEDURE FOR OVERSIGHT SOP No: P08/PF2 V2 Effective Date: 31 st July 2013 Supersedes: P08/PF2 Revision Date: 31 st March 2014 Author: Position: Approved
More informationANNEX. CHAPTER I General principles
ANNEX REGULATIONS on the authorisation by the NMA of clinical trials/notification to the National Medicines Agency of non-interventional studies on medicinal products for human use in Romania CHAPTER I
More informationAudit Program Background Definition Management Example Content Risk assessment approach
AUDIT PROGRAM Audit Program Background Definition Management Example Content System audits vs study audits Risk assessment approach ICH-GCP E6 new content Management Example 2 Background - Definition There
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Audits and Inspections SOP-QMS-004 Version Number 4 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s)
More informationINSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience
INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland Question 1: What laws or regulations apply to an application for conducting a clinical
More informationGUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN MAKING AN ASSESSMENT OF CLINICAL INVESTIGATION NOTIFICATION
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.2 December 2008 GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationSTUDY CLOSURE AND ARCHIVING
STUDY CLOSURE AND ARCHIVING DOCUMENT NO.: CR009 v2.0 AUTHOR: Lynn Smith ISSUE DATE: 15 August 2016 EFFECTIVE DATE: 29 August 2016 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research
More informationECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies
ECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies SOP number: ECTU TM 17 Signature Date Authored by: Holly Ennis, Trial Manager 6 th Sept 2017 Reviewed by: Laura Forsyth, Trial Manager
More informationHospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)
Page 1 of 8 Hospital Authority (HA) Guide on Research Ethics (for Study Site & Version Effective Date 2 01/02/2015 Document Number HAHO-CE&TM-HA REC Author HA Head Office Steering Committee on Research
More informationAuthor Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document
SOP Title: Investigator s Brochure Content, Design, Amendments, Filing & Distribution Author: Clinical Research and Development Office (CRDO) Author Signature: Date: 10 October 2017 The author is signing
More informationCompetence in Clinical Trials the Regulators Perspective.. (Jennifer Martin Senior GCP Inspector, 9 June 2014)
Competence in Clinical Trials the Regulators Perspective. (Jennifer Martin Senior GCP Inspector, 9 June 2014) Requirements Statutory Instrument 2004/1031 (as amended) Regulation 28(2): The sponsor (and
More informationQUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION
PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PS/W 1/2011 2 Annexes 22 July 2011 QUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION PIC/S 2011 Reproduction
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationStandard Operating Procedure: Obtaining Informed Consent from Competent Adults for Research Studies. SOP Number: UoA-NHSG-SOP-010 Version No: 2
Standard Operating Procedure: Obtaining Informed Consent from Competent Adults for Research Studies SOP Number: UoA-NHSG-SOP-010 Version No: 2 Author: Date: 27 th March 2015 (Carole Edwards, Lead Research
More informationResearch Governance Policy
Research Governance Policy Version: Status: Title of originator/author: Name of responsible director: Developed/revised by group/committee and Date: Approved by group/committee and Date: Effective date
More informationGood Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations
Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.
More informationRSC/CT Det. no. 1/2013
RSC/CT Det. no. 1/2013 Protocol 1631-P The English version of this Determination was prepared in order to help comprehension by non-italian mother tongue users, but is NOT an official document. Please
More informationClinical Trials application process, legislation & guidelines
Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission
More informationHOSPITAL AUTHORITY (HA) GUIDE
Page 1 of 14 HOSPITAL AUTHORITY (HA) GUIDE ON RESEARCH ETHICS (for Study Site & Research Ethics Committee) Revision Number: 1 (The document supersedes HA RE001 Hospital Authority Guide for Cluster Research
More informationWorkstream 6: Pharmacovigilance
Workstream 6: Pharmacovigilance 1.0 Introduction... 2 1.1 Background... 2 1.2 Definitions... 3 2.0 Definition of Sponsor for Pharmacovigilance... 4 3.0 General Considerations: Risk Adapted Approaches to
More informationPERFORMANCE IN INITIATING AND DELIVERING CLINICAL RESEARCH INFORMATION SUBMISSION GUIDELINES
PERFORMANCE IN INITIATING AND DELIVERING CLINICAL RESEARCH INFORMATION SUBMISSION GUIDELINES Version Control Item 19 Items 25, 26 Item 29 Update to the Publication requirements Update of Submission Timetable
More informationMarie-Claire Rickard, RG and GCP Manager Cheryl Lawrence, Senior Research Pharmacist Damien Kelly, Barts Pharmacy Site and Clinical Trials Lead
Standard Operating Procedures (SOP) for: Pharmacy Involvement in Hosted Studies SOP Number: 42b Version Number: 2.0 Effective Date: 23 rd November 2015 Review Date: 2 nd November 2017 Author: Reviewer:
More informationPROTOCOL DRAFTING GUIDE
MUHC Research Ethics Board (Neurosciences & Psychiatry) Comité d éthique de la recherche du MUHC (Neurosciences & psychiatrie) PROTOCOL DRAFTING GUIDE LIST OF ITEMS TO BE INCLUDED IN A PROTOCL FOR RESEARCH
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical
More informationImpact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004
Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationAgenzia Italiana del Farmaco
Agenzia Italiana del Farmaco The Italian Legislation and the work of the Italian Medicines Agency (AIFA) in the field of ethics of Clinical Trials Umberto Filibeck AIFA Head of GCP Inspectorate and GCP
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Trial Master File & Investigator Site File SOP number: TM 001 SOP category: Trial Management Version number: 03 Version
More informationNew Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012
New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public
More informationMEDICINES CONTROL COUNCIL
Clinical Trial Application Form MEDICINES CONTROL COUNCIL APPLICATION TO CONDUCT A CLINICAL TRIAL Study title Protocol No. Version No. Study Drug MCC Ref. no. (if applicable) MCC Ref number(s) of comparator
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Creation & Maintenance of an Investigator Brochure SOP Number: 34 Version Number: 1.0 Supercedes: N/A Effective date: August
More informationDATA QUALITY POLICY. Version: 1.2. Management and Caldicott Committee. Date approved: 02 February Governance Lead
DATA QUALITY POLICY Version: 1.2 Approved by: Date approved: 02 February 2016 Name of Originator/Author: Name of Responsible Committee/Individual: Information Governance, Records Management and Caldicott
More informationHow to Apply for Ethics (Non-CTIMPs) including Sponsorship
How to Apply for Ethics (Non-CTIMPs) including Sponsorship Joint Research & Enterprise Office (JREO) St George s University of London Lucy H H Parker Clinical Research Governance Manager Joint Research
More informationGUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS
1. PURPOSE This guideline is about the collection, verification, and submission of the reports of adverse events / reactions occurring in clinical drug trials, and code breaking methods. 2. DEFINITIONS
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationQuality Assurance in Clinical Trials
Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:
More informationGood Clinical Practice
Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie
More informationTrack III: International Clinical Trials: Global Compliance Norms and EU Focus
Track III: International Clinical Trials: Global Compliance Norms and EU Focus EU Focus Emmanuelle Voisin, PhD Principal, Voisin Consulting May 2008 Rationale Clinical trials in EU important part of health
More informationConfirming Research Study Capacity and Capability
Title: Outcome Statement: Written By: Confirming Research Study Capacity and Capability Researchers will be informed about the procedures and requirements for obtaining permission to conduct a research
More informationPrimary Care mcta 2013: Guidance for use
GUIDANCE ON USE OF THE MODEL CLINICAL TRIAL AGREEMENT FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY SPONSORED RESEARCH IN PRIMARY CARE (PRIMARY CARE mcta, 2013 VERSION) Background to the development
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Training and Development SOP-QMS-007 Version Number 2 Issue Date 15 Apr 2016 Effective Date 26 May 2016 Review Date 26 May 2018 Author(s) Reviewer(s)
More informationIRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010
IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More informationGuidance on conducting consultations in the HRA Internal HRA guidance only
Guidance on conducting consultations in the HRA Internal HRA guidance only Author: Amanda Hunn Date of Release: 19 th February 2015 Version No. & Status: v.1.0 Final Approved by: EMT Supersedes Version:
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/813938/2011 Rev 3* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 3) Date for coming into effect of first version 2 July 2012
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Medicinal Product quality, safety and efficacy Brussels, 16 August 2013 EudraLex The Rules Governing Medicinal
More informationClinical trials from CRA s point of view
Clinical trials from CRA s point of view Dr Jacek S Gregorczyk MPharmS, PhD Clinical Research Associate (CRA) at MDS Pharma Services UK office - a global CRO REGULATION of CLINICAL TRIALS World Medical
More informationSubmitting a CTA application to the MHRA
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationGood Clinical Practice
Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete
More informationSupply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017
Supply of aseptically - prepared doses of IMPs across legal boundaries Edition 1 December 2017 Endorsed and supported by: NHS Pharmaceutical Quality Assurance Committee 2017 with National Pharmacy Clinical
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/816292/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module VII Periodic safety update report Draft finalised by the Agency in collaboration with Member
More informationCODE OF PRACTICE FOR RESEARCH
CODE OF PRACTICE FOR RESEARCH Dr Diana Leighton REF Manager Professor Andy Young Director of Research & Innovation Services Version 1.0 - September 2010 First approved Academic Board 27 September 2010
More informationRoles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)
Last revision: 16 September 2010 EMA/537415/2008 Human Medicines Development and Evaluation Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of
More informationStorage of Clinical Trials Materials and Investigational Medicinal Products
York Foundation Trust R&D Unit Standard Operating Procedure Pharm/S47 Storage of Clinical Trials Materials and Investigational Medicinal Products IT IS THE RESPONSIBILITY OF ALL USERS OF THIS SOP TO ENSURE
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationData Quality and Integrity: From Clinical Monitoring to Marketing Approval
Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November 2010 1 Objectives Identify the importance of accuracy,
More informationRegulatory and ethical requirements in medical device studies. Finland
Regulatory and ethical in medical device studies Finland SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within
More informationetmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector
etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector Agenda EU Legislation and Guidance News/Updates relating to TMF Structure and Content of e/tmf Inspecting etmfs
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and
More informationHuman Samples in Research
Human Samples in Research Import and Export of Human Tissue Document Identifier HTA-06-SOP-Import and Export AUTHOR APPROVER EFFECTIVE DATE: Name and role Signature and date Name and role Signature and
More informationReflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples
1 2 3 26 August 2010 EMA/INS/GCP/532137/2010 GCP Inspectors Working Group 4 5 6 Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples Draft Adoption
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationPREPARING TO RUN A TRIAL
PREPARING TO RUN A TRIAL PHASE 1 STUDIES This phase is designed to assess the safety (pharmacovigilance), tolerability, pharmacokinetics, and pharmacodynamics of a drug. STUDY DESIGN Phase I clinical trials
More informationCMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES
CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES 1. INTRODUCTION (BACKGROUND) November 2007 According to Article 8
More informationA notice on the issuance of drug clinical trials, ethical review of the guiding principles
药物临床试验伦理审查工作指导原侧.doc 的翻译 A notice on the issuance of drug clinical trials, ethical review of the guiding principles State Food and Drug Administration Note [2010] No. 436 November 2, 2010 Release A notice
More informationWhat s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance
Vol. 9, No. 2, February 2013 Happy Trials to You What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Reprinted from the Guide to Good Clinical Practice with permission of Thompson Publishing
More informationReflection paper on GCP compliance in relation to trial master files (paper and/or electronic) for management, audit and inspection of clinical trials
1 2 3 4 5 6 7 1 February 2013 EMA/INS/GCP/636736/2012 Good Clinical Practice Inspectors Working Group (GCP IWG) Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic)
More informationSOP04: Standard Operating Procedure for Trial Supplies and Labelling
SOP04: Standard Operating Procedure for Trial Supplies and Labelling Authorship Team: Anne Seagrove & Mair Roberts Joint SOP Group on Trial Administration (viz Angela Evans, Sarah Gaze, Hayley Hutchings,
More informationQualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008
Qualified Persons in the Pharmaceutical Industry Code of Practice March 2008 Updated October 2009 Code of Practice for Qualified Persons 1. INTRODUCTION... 1 2. REGULATORY BASIS FOR THE QUALIFIED PERSON...
More informationEMA pharmacovigilance system manual
13 October 2016 EMA/623550/2013 Inspections, Human Medicines Pharmacovigilance & Committees Division Version 1.2 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000
More informationHouse of Commons Science and Technology Committee: Inquiry on clinical trials and disclosure of data
House of Commons Science and Technology Committee: Inquiry on clinical trials and disclosure of data Evidence submitted by the Medical Research Council, 26 February 2013 Introduction 1. The Medical Research
More informationReport. Quality Assessment of Internal Audit at <Organisation> Draft Report / Final Report
Report Quality Assessment of Internal Audit at Draft Report / Final Report Quality Self-Assessment by Independent Validation by Table of Contents 1.
More informationComputer System Validation & Backup
REFERENCE: VERSION NUMBER: 1.1 EFFECTIVE DATE: 28-03-18 REVIEW DATE: 28-03-20 AUTHOR: Clinical Trials Manager, Clinical Trials Officer REVIEWED BY: R&I Senior Team APPROVED BY: Deputy Director of Research
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 28, 2010 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationMEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155
MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part
More informationEssential Healthcare Research Governance Processes. Cindy Cooper, Lindsay Unwin and Judith Cohen, UoS
Essential Healthcare Research Governance Processes Cindy Cooper, Lindsay Unwin and Judith Cohen, UoS Aims Overview of governance processes including recent changes to remit Reminder of HoD and PI responsibilities
More informationISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual
The StAmP Trial: A Proof of Principle, double blind, Randomised Placebo-Controlled, Multi Centre Trial of Statins to Ameliorate Early Onset Pre-eclampsia. ISRCTN: 23410175 EudraCT Number: 2009-012968-13
More information